Nanogenics Update
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to provide an update on its subsidiary, Nanogenics Limited ("Nanogenics").
Nanogenics has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at Kings College, London.
Nanogenics' ECP105 product for the recovery of post-surgical treatment of Glaucoma contains a proprietary siRNA sequence to silence the fibrotic gene MRTF-B. Glaucoma patients who have failed to respond to medication need surgery to lower intraocular pressure which causes fibrosis at the surgery site. This fibrosis often leads to failure of the surgery and frequently patients have to undergo further surgery. ECP105 is intended for injection into the ocular cavity to switch off the gene responsible for the fibrosis. Unlike current off-label treatment using toxic chemotherapy drugs, ECP105 is intended for repeat use to prevent the need for further surgery.
The work involves creating and testing a novel formulation containing Nanogenics' proprietary siRNA sequence to undertake a proof of concept in-vivo study, to demonstrate that a single dose of its Glaucoma surgery treatment ECP105 can match the anti-fibrotic effect of current post surgical treatment using Mitomycin C, but without the cytotoxic side effects seen with this approach.
Nigel Theobald, Chief Executive Officer of the Company, commented:
"We are very excited for the potential of ECP105, which is a unique product for an unmet clinical need in the ophthalmology market. More than 75 million people worldwide are affected by Glaucoma and the total Glaucoma treatment market size in 2021 exceeded $5.5 billion and is growing. A novel product in this space alone represents a good opportunity for Nanogenics and importantly the antifibrotic siRNA sequence can also be used to investigate other fibrotic treatments for liver and lung fibrosis."
| N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director Engage with us directly at N4 Pharma Investor Hub To hear more, visit | Via N4 Pharma Investor Hub Sign up at investors.n4pharma.com https://investors.n4pharma.com/link/GyVdGr |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44(0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope | Tel: +44(0)20 3657 0050 |
| IFC Advisory Ltd Financial PR Graham Herring Zach Cohen | Tel: +44(0)20 3934 6630 |
About N4 Pharma
For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.